Melinda Collier told Newsweek that "you can't and shouldn't chalk up someone, let alone a child, as a lost cause." ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The Cleveland ...

Scientists at the Francis Crick Institute have found a new treatment target for CDKL5 deficiency disorder (CDD), one of the most common types of genetic epilepsy. CDD causes seizures and impaired ...

From June 27 to 29 at the Holiday Inn Parco Dei Medici in Rome, the international congress "CDKL5 All InVolved" will be held, with about 300 participants including families, children affected by CDKL5 ...

CDKL5 Deficiency Disorder (CDD) is a devastating neurodevelopmental disorder caused by mutations in the CDKL5 gene. The Loulou Foundation, a private non-profit foundation dedicated to the development ...

Scientists at the Francis Crick Institute have found a new treatment target for CDKL5 deficiency disorder (CDD), one of the most common types of genetic epilepsy. CDD causes seizures and impaired ...

The rare genetic disease CDKL5 Deficiency Disorder (CDD) has been designated with a new disease code in the International Classification of Diseases (ICD), the medical classification list from the ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Full data have been published on ganaxolone (Ztalmy) for cyclin ...

CDKL5 deficiency disorder (CDD) is an ultra-rare, severe DEE with an onset in early infancy with a high unmet need, and has limited treatment options CDD affects approximately 1 in 40,000 to 60,000 ...

Abcam has announced a research collaboration with the Loulou Foundation to discover new tools to advance research for the development of therapeutics for CDKL5 Deficiency Disorder. Abcam has announced ...

Soticlestat continues to appear to be safe and well-tolerated; the majority of the 11 patients showed a reduction in seizures All patients that have completed the Phase 2 ARCADE study to date have ...

The mechanism behind a type of genetic epilepsy known as CDKL5 deficiency disorder has been elucidated, highlighting a potential target for novel therapeutic approaches. In a recent paper, researchers ...